Cargando…

P60 EVOLVING OUTCOMES OF EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA: 20-YEARS SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Palumbo, F., Orofino, A., Del Fabro, V., Fazio, M., Elia, F., Esposito, B., Frazzetto, S., Romano, A., Di Raimondo, F., Conticello, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Poster
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171479/ http://dx.doi.org/10.1097/01.HS9.0000936368.13093.f4

Ejemplares similares

A rare case of multiple myeloma with intracranial extramedullary relapse: One or more myeloma clones?
por: Markovic, Uros, et al.
Publicado: (2019)

Multiple Myeloma in 2023 Ways: From Trials to Real Life
por: Fazio, Manlio, et al.
Publicado: (2023)

P43 CIRCULATING CLONAL PLASMA CELLS AT START OF SALVAGE REGIMEN PROVIDE POWERFUL PROGNOSTICATION BIOMARKER IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE
por: Romano, A., et al.
Publicado: (2023)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

P59 ACTIVE TREATMENT AND LOW IGM ARE ASSOCIATED WITH INFERIOR SARS-COV-2 SPIKE ANTIBODY RESPONSE TO THREE DOSES OF COVID-19 RNA VACCINATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Duminuco, A., et al.
Publicado: (2023)

Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils
por: Romano, Alessandra, et al.
Publicado: (2021)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

PB2093: OVERALL SURVIVAL IN RELAPSED-REFRACTORY MYELOMA PATIENTS DEPENDS ON CIRCULATING PLASMA CELLS QUANTITATION
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab
por: Duminuco, Andrea, et al.
Publicado: (2023)

P26: EXTRAMEDULLARY MULTIPLE MYELOMA: A MONOCENTRIC RETROSPECTIVE OBSERVATIONAL STUDY
por: Brescini, M, et al.
Publicado: (2022)

Serum free light chains and multiple myeloma: Is it time to extend their application?
por: Markovic, Uros, et al.
Publicado: (2020)

Role of Serum Free Light Chain Assay in Relapsed/Refractory Multiple Myeloma. A Real-Life Unicentric Retrospective Study
por: Markovic, Uros, et al.
Publicado: (2021)

Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study
por: Del Fabro, Vittorio, et al.
Publicado: (2023)

PB2279: REDUCED ABSOLUTE COUNT OF MONOCYTES IN PATIENTS CARRYING HEMATOLOGICAL NEOPLASMS AND SARS-COV2 BREAKTHROUGH INFECTION
por: Romano, A., et al.
Publicado: (2022)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

P02 ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMACELLS
por: Romano, A., et al.
Publicado: (2023)

P1558: PROPHYLAXIS WITH TIXAGEVIMAB-CILGAVIMAB IN SINGLE-CENTER EXPERIENCE CAN REDUCE SEVERE COMPLICATIONS RELATED TO SARS-COV-2 INFECTION IN HEMATOLOGICAL PATIENTS
por: Duminuco, Andrea, et al.
Publicado: (2023)

Oral Lesion as Unusual First Manifestation of Multiple Myeloma: Case Reports and Review of the Literature
por: Romano, A., et al.
Publicado: (2014)

An imaging review of extramedullary myeloma
por: Kay, M, et al.
Publicado: (2015)

Characteristics and prognostic value of extramedullary chromosomal abnormalities in extramedullary myeloma
por: Xia, Yuan, et al.
Publicado: (2022)

Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy Via STAT3
por: Puglisi, Fabrizio, et al.
Publicado: (2019)

Extramedullary disease in multiple myeloma
por: Bansal, Radhika, et al.
Publicado: (2021)

Immunological Dysregulation in Multiple Myeloma Microenvironment
por: Romano, Alessandra, et al.
Publicado: (2014)

Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
por: Parisi, Marina Silvia, et al.
Publicado: (2019)

Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement
por: Español, Ignacio, et al.
Publicado: (2017)

CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment
por: Giallongo, Cesarina, et al.
Publicado: (2022)

P01 LACTATE TRAFFICKING INHIBITION RESTORES SENSITIVITY TO PROTEASOME INHIBITHORS AND ORCHESTRATES IMMUNOMICROENVIRONMENT IN MULTIPLE MYELOMA
por: Giallongo, C., et al.
Publicado: (2023)

Multiple myeloma with huge extramedullary plasmacytomas
por: Bae, Soo-Young, et al.
Publicado: (2010)

Extramedullary Multiple Myeloma with Hepatic Involvement
por: Singh, Manpreet, et al.
Publicado: (2021)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Genetic Abnormalities in Extramedullary Multiple Myeloma
por: McAvera, Roisin, et al.
Publicado: (2023)

P852: ARGININE DEPRIVATION INDUCES ACQUISITION OF A SENESCENT PHENOTYPE AND FAVORS GENOMIC INSTABILITY IN MULTIPLE MYELOMA PLASMA CELLS
por: Romano, Alessandra, et al.
Publicado: (2023)

Evolving treatment strategies for myeloma
por: Morgan, G J, et al.
Publicado: (2005)

Advances in the treatment of extramedullary disease in multiple myeloma
por: Li, Yating, et al.
Publicado: (2022)

Multifocal Extramedullary Plasma Cell Myeloma of the Colon
por: Karime, Christian, et al.
Publicado: (2023)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)
por: Giallongo, Cesarina, et al.
Publicado: (2016)

Evolving therapeutic role of bisphosphonates in multiple myeloma
por: Ural, A U, et al.
Publicado: (2005)

Salvage Therapy of Multiple Myeloma: The New Generation Drugs
por: Romano, Alessandra, et al.
Publicado: (2014)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oct32mk7fnqi2afb21ur4e3uvk